Finance

Lists
XERS:NASDAQ
Xeris Biopharma Holdings Inc
$16.65
+0.79%
(+0.13) 1D
$16.65
0.00% (0.00)
After hours
Closed: Nov 12, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XERS...
Open
$16.69
High
$16.88
Low
$16.35
Mkt. cap
3.04B
Avg. vol.
3.12M
Volume
0.00
52-wk high
$16.88
52-wk low
$5.25
EPS
-$0.06
Beta
0.82
Shares outstanding
182.70M
No. of employees
435
Open
$16.69
High
$16.88
Low
$16.35
Mkt. cap
3.04B
Avg. vol.
3.12M
Volume
0.00
52-wk high
$16.88
52-wk low
$5.25
EPS
-$0.06
Beta
0.82
Shares outstanding
182.70M
No. of employees
435
News stories
From web sources and news partners
About Xeris Biopharma Holdings Inc
CEO-
Employees435
Founded2005
HeadquartersChicago, Illinois, United States
SectorHealth Care
IndustryPharmaceutical industry
Websitexerispharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to XERS in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for XERS in the last 3 months.
Highest
Current $16.65
$21.00 (+26.13%)
Average
$17.17 (+3.12%)
Lowest
$12.00 (-27.93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jenna Davidner
Barclays
Buy
Maintained
$18.00
+8.1%
11/11/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$18.00
+8.1%
11/09/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$21.00
+26.1%
11/06/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
$18.00
+8.1%
11/06/2026
David Amsellem
Piper Sandler
Hold
Reiterated
$12.00
-27.9%
11/06/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$18.00
+8.1%
09/10/2026
Roanna Ruiz
Leerink Partners
Buy
Reiterated
$16.00
-3.9%
09/10/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$0.06 / $0.03
+124.97%beat
Revenue / Est. (USD)
107.22M / 101.68M
+5.45%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
85.81M
83.13M
92.10M
107.22M
Cost of goods sold
10.95M
10.57M
12.51M
12.43M
Cost of revenue
10.95M
10.57M
12.51M
12.43M
Research and development expenses
7.87M
8.78M
10.67M
11.06M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
47.50M
53.14M
61.04M
64.11M
Operating expense
58.09M
64.64M
74.42M
77.88M
Total operating expenses
69.03M
75.21M
86.93M
90.31M
Operating income
16.77M
7.92M
5.17M
16.92M
Other non operating income
-
-
-
-
EBT including unusual items
11.08M
2.23M
-31.10M
11.29M
EBT excluding unusual items
11.08M
2.23M
-319.00K
11.29M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
11.08M
2.23M
-31.10M
11.29M
Net profit margin
12.91%
2.69%
-33.77%
10.53%
Earnings per share
0.06
0.01
-0.00
0.06
Interest and investment income
1.46M
1.20M
1.46M
827.00K
Interest expense
-7.15M
-6.88M
-6.95M
-6.46M
Net interest expenses
-5.69M
-5.68M
-5.49M
-5.63M
Depreciation and amortization charges
-
-
-
-
EBITDA
19.82M
10.96M
8.21M
19.95M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps